17
Participants
Start Date
November 15, 2017
Primary Completion Date
July 26, 2021
Study Completion Date
July 6, 2023
Avelumab
Avelumab will be administered intravenously as an infusion, at a dose of 10 milligram per kilogram once every 2 weeks, until occurence of progressive disease, unacceptable toxicity, or any of the other criteria for withdrawal listed in the protocol .
Sunnybrook Health Sciences Centre, Toronto
Merck KGaA, Darmstadt, Germany
INDUSTRY
Sunnybrook Health Sciences Centre
OTHER